Mestre
Mestre
Mestre, Italy21 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease | Chronic Disease, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, chronic obstructive pulmonary disease, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 3 | 2026-10-02 | NCT06283966 | |
| Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia | Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Active, not recruiting | Not stated | 2026-09-30 | NCT04579367 | |
| FARAPULSE Workflow Assessment Registry | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder | Active, not recruiting | Not stated | 2026-09-24 | NCT06656884 | |
| Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Recruiting | Not stated | 2026-09-16 | NCT02071134 | |
| Vercise™ DBS Dystonia Prospective Study | Dyskinesias, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, dystonic disorder, nervous system disorder | Recruiting | Not stated | 2026-09-11 | NCT02686125 | |
| Transfemoral TAVI With or Without Coronary Angiogram in Patients With Severe Aortic Stenosis (PURE TAVI) | Ventricular Outflow Obstruction, aortic valve disorder, aortic valve stenosis, cardiovascular disorder, heart disorder, heart valve disorder | Enrolling by invitation | Not applicable | 2026-08-25 | NCT06898086 | |
| A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Recruiting | Phase 3 | 2026-08-24 | NCT07000357 | |
| Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-07-16 | NCT03610438 | |
| Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Site, acquired polycythemia vera, bone marrow disorder, bone marrow neoplasm, hematologic disorder, hematopoietic and lymphoid system neoplasm, neoplasm | Recruiting | Not stated | 2026-07-09 | NCT06506084 | |
| Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) | Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-04-30 | NCT04608318 | |
| Functional Assessment in Elderly MI Patients With Multivessel Disease | Infarction, Necrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, heart disorder, ischemic disease, myocardial infarction, myocardial ischemia, vascular disorder | Active, not recruiting | Not applicable | 2026-04-02 | NCT03772743 | |
| Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-03-06 | NCT05306301 | |
| TRAns-Femoral Access Intravascular Lithotripsy Comparison With PTA in TAVI | Nutritional and Metabolic Diseases, calcinosis, calcium metabolic disease, metabolic disease | Recruiting | Not stated | 2025-05-16 | NCT05873842 | |
| Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT) | High-risk MDS | Recruiting | Phase 3 | 2025-04-29 | NCT04184505 | |
| OLIGOS: Impact of Treatment on Primary Tumour in Patients With Newly Diagnosed Oligometastatic Neoplasia of the Prostate | Oligometastatic Prostate Carcinoma | Recruiting | Not stated | 2025-04-17 | NCT06273345 | |
| Study on the Diagnosis and Management of CLL in Italy by GIMEMA | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Not stated | 2025-03-14 | NCT04867915 | |
| Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenoma, epithelial neoplasm, lung disorder, lung neoplasm, malignant mesothelioma, mesothelial neoplasm, mesothelioma, neoplasm, pleural neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2025-03-13 | NCT04996017 | |
| Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2025-01-23 | NCT04722848 | |
| Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2024-11-08 | NCT04168502 | |
| Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2024-10-22 | NCT04475731 | |
| Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2022-08-26 | NCT04442412 |